Long-term Outcome of Acute Myeloid Leukemia after Benzene Exposure

From General Health to Occupational Risk

For decades, public health resources have provided general guidance on maintaining wellness and understanding common medical conditions. This legacy of accessible health information has empowered individuals to recognize symptoms and seek appropriate care across a wide range of concerns, from minor ailments to chronic diseases. The foundational principle has always been to translate complex medical knowledge into actionable advice for everyday life. Building on this tradition of translating health science for practical benefit, we now turn to a more specialized area of occupational health. In industrial settings, workers may encounter chemical agents that require careful monitoring and risk assessment. One such agent is benzene, a solvent widely used in manufacturing processes. Prolonged or high-level exposure to benzene has been linked to specific health outcomes that demand focused attention from both medical professionals and workplace safety regulators. Understanding the long-term implications of such exposure is critical for developing effective surveillance protocols and treatment strategies. This transition from general health literacy to targeted occupational concern allows us to apply the same principles of clear communication and evidence-based guidance to a population facing distinct environmental risks.

Benzene and Acute Myeloid Leukemia: The Evidence

Benzene is a well-established myelotoxin and recognized human carcinogen. Chronic exposure to benzene is a known risk factor for the development of acute myeloid leukemia (AML), a hematologic malignancy characterized by the rapid proliferation of abnormal myeloid progenitor cells in the bone marrow and peripheral blood. The clinical presentation of AML typically includes symptoms related to bone marrow failure, such as fatigue, pallor, infection, and bleeding, along with signs of extramedullary involvement. Diagnosis is confirmed by bone marrow aspiration and biopsy demonstrating at least 20% blasts of myeloid lineage, along with cytogenetic and molecular profiling to guide prognosis and treatment. Benzene is metabolized in the liver and bone marrow to reactive intermediates, including benzene oxide, phenol, hydroquinone, and 1,4-benzoquinone. These metabolites can cause direct DNA damage, oxidative stress, and epigenetic alterations. The carcinogenic ability of benzene has been reported, and chronic exposure can be one of the risk elements for solid cancers and hematological neoplasms (https://pubmed.ncbi.nlm.nih.gov/34069279/). Possible mechanisms of benzene initiation of hematological tumors include genotoxic effects, action on oxidative stress and inflammation, and provocation of immunosuppression (https://pubmed.ncbi.nlm.nih.gov/34069279/). However, it is becoming evident that genetic alterations and other causes are insufficient to fully justify several phenomena that influence the onset of hematologic malignancies (https://pubmed.ncbi.nlm.nih.gov/34069279/). Occupational exposure to benzene at levels of 10 ppm or more has been associated with increased risk of AML (https://pubmed.ncbi.nlm.nih.gov/33429013/). The mode of action for AML development leading to mortality is anticipated to include multiple earlier key events, which can be observed in hematotoxicity and genetic toxicity in peripheral blood of exposed workers (https://pubmed.ncbi.nlm.nih.gov/33429013/). Prevention of these early events would lead to prevention of the apical, adverse outcomes, the morbidity and mortality caused by myelodysplastic syndromes (MDS) and AML (https://pubmed.ncbi.nlm.nih.gov/33429013/). Incorporation of key event information should modify the risk model, but few modification approaches have been suggested (https://pubmed.ncbi.nlm.nih.gov/33429013/).

Epidemiological Studies and Risk Quantification

Epidemiological studies have consistently demonstrated an elevated risk of AML following benzene exposure. A meta-analysis of 25 studies found increased risks of all childhood cancers and acute myeloid leukemia associated with benzene exposure, with an odds ratio for AML of 1.22 (95% CI: 1.02-1.46) per 1 μg/m³ increase in benzene exposure (https://pubmed.ncbi.nlm.nih.gov/41485753/). In a large Swiss National Cohort study of approximately 2.97 million persons and 13,415 lymphohaematopoietic cancer cases, including 3,055 cases with benzene exposure, increased mortality risks per unit increase in continuous benzene exposure were observed for AML (hazard ratio 1.03, 95% CI 1.00-1.06) (https://pubmed.ncbi.nlm.nih.gov/38727681/). When exposure was assessed categorically, increasing trends in risks were observed with increasing benzene exposure for AML (P=0.04) (https://pubmed.ncbi.nlm.nih.gov/38727681/). Previous studies established a causal relationship between occupational benzene exposure and AML (https://pubmed.ncbi.nlm.nih.gov/38727681/).

Prognosis and Long-term Outcomes

The prognosis for patients with AML after benzene exposure is influenced by several factors, including patient age, cytogenetic and molecular abnormalities, and response to initial therapy. The timeline between benzene exposure and documented harm can vary widely, with latency periods ranging from several months to decades. The risk of AML increases with cumulative exposure, and the mode of action includes multiple key events that can be observed in hematotoxicity and genetic toxicity in peripheral blood of exposed workers (https://pubmed.ncbi.nlm.nih.gov/33429013/). Adequacy of warnings regarding benzene and AML is critical for prevention. Occupational exposure limits and safety data sheets should clearly communicate the carcinogenic risk and the need for exposure monitoring and control. However, the effectiveness of such warnings depends on compliance and enforcement. In summary, benzene exposure is a well-documented cause of AML, with a mode of action involving genotoxicity, oxidative stress, and epigenetic effects. The prognosis for affected patients is generally poor, with long-term survival rates depending on disease subtype and treatment response. Prevention of early hematotoxic and genotoxic events is key to reducing the burden of benzene-induced AML.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between benzene exposure and acute myeloid leukemia?

Benzene is a known human carcinogen that can cause acute myeloid leukemia (AML). Chronic exposure to benzene, especially at levels of 10 ppm or more, increases the risk of developing AML. The mechanism involves genotoxicity, oxidative stress, and epigenetic alterations caused by benzene metabolites. Epidemiological studies have consistently shown elevated risks, with a meta-analysis reporting an odds ratio of 1.22 per 1 μg/m³ increase in benzene exposure (https://pubmed.ncbi.nlm.nih.gov/41485753/).

What is the long-term prognosis for AML patients with a history of benzene exposure?

The prognosis for AML patients after benzene exposure depends on factors such as age, cytogenetic and molecular abnormalities, and response to initial therapy. The latency period between exposure and diagnosis can range from months to decades. Overall, the prognosis is generally poor, with long-term survival rates varying by disease subtype and treatment response. Prevention of early hematotoxic and genotoxic events is crucial to reduce the burden of benzene-induced AML.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Benzene exposure and a confirmed Acute Myeloid Leukemia diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.